Literature DB >> 22254513

A method for selecting an efficient diagnostic protocol for classification of perceptive and cognitive impairments in neurological patients.

Kunjan D Rana1, Benvy Caldwell, Lucia M Vaina.   

Abstract

An important and unresolved problem in the assessment of perceptual and cognitive deficits in neurological patients is how to choose from the many existing behavioral tests, a subset that is sufficient for an appropriate diagnosis. This problem has to be dealt with in clinical trials, as well as in rehabilitation settings and often even at bedside in acute care hospitals. The need for efficient, cost effective and accurate diagnostic-evaluations, in the context of clinician time constraints and concerns for patients' fatigue in long testing sessions, make it imperative to select a set of tests that will provide the best classification of the patient's deficits. However, the small sample size of the patient population complicates the selection methodology and the potential accuracy of the classifier. We propose a method that allows for ordering tests based on having progressive increases in classification using cross-validation to assess the classification power of the chosen test set. This method applies forward linear regression to find an ordering of the tests with leave-one-out cross-validation to quantify, without biasing to the training set, the classification power of the chosen tests.

Entities:  

Mesh:

Year:  2011        PMID: 22254513      PMCID: PMC3743413          DOI: 10.1109/IEMBS.2011.6090264

Source DB:  PubMed          Journal:  Conf Proc IEEE Eng Med Biol Soc        ISSN: 1557-170X


  17 in total

1.  The Newcastle Auditory Battery (NAB). A temporal and spatial test battery for use on adult naïve subjects.

Authors:  T D Griffiths; J L Dean; W Woods; A Rees
Journal:  Hear Res       Date:  2001-04       Impact factor: 3.208

2.  Intact "biological motion" and "structure from motion" perception in a patient with impaired motion mechanisms: a case study.

Authors:  L M Vaina; M Lemay; D C Bienfang; A Y Choi; K Nakayama
Journal:  Vis Neurosci       Date:  1990-10       Impact factor: 3.241

3.  Regional cerebral correlates of global motion perception: evidence from unilateral cerebral brain damage.

Authors:  L M Vaina; A Cowey; R T Eskew; M LeMay; T Kemper
Journal:  Brain       Date:  2001-02       Impact factor: 13.501

4.  A selective impairment of motion perception following lesions of the middle temporal visual area (MT).

Authors:  W T Newsome; E B Paré
Journal:  J Neurosci       Date:  1988-06       Impact factor: 6.167

5.  A lesion of cortical area V2 selectively impairs the perception of the direction of first-order visual motion.

Authors:  L M Vaina; S Soloviev; D C Bienfang; A Cowey
Journal:  Neuroreport       Date:  2000-04-07       Impact factor: 1.837

6.  Deficits of motion integration and segregation in patients with unilateral extrastriate lesions.

Authors:  Lucia M Vaina; Alan Cowey; Marianna Jakab; Ron Kikinis
Journal:  Brain       Date:  2005-06-23       Impact factor: 13.501

7.  Perceptual deficits in patients with impaired recognition of biological motion after temporal lobe lesions.

Authors:  Lucia M Vaina; Charles G Gross
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-19       Impact factor: 11.205

8.  Visual deficits in a patient with 'kaleidoscopic disintegration of the visual world'.

Authors:  L M Vaina; A Cowey; M LeMay; D C Bienfang; R Kikinis
Journal:  Eur J Neurol       Date:  2002-09       Impact factor: 6.089

9.  Functional and anatomical profile of visual motion impairments in stroke patients correlate with fMRI in normal subjects.

Authors:  Lucia M Vaina; Elif M Sikoglu; Sergei Soloviev; Marjorie LeMay; Salvatore Squatrito; Gabriella Pandiani; Alan Cowey
Journal:  J Neuropsychol       Date:  2009-10-08       Impact factor: 2.864

10.  Selective impairment of visual motion interpretation following lesions of the right occipito-parietal area in humans.

Authors:  L M Vaina
Journal:  Biol Cybern       Date:  1989       Impact factor: 2.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.